SCHEMBL3777440

SCHEMBL3777440

COc1cccc(N2CCN(CC(=O)N3CCN(C4CCCCC4)CC3)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
KMT2A Q03164 5/20 0.55
MEN1 O00255 4/20 0.55
ALDH1A1 P00352 4/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GFER P55789 3/20 0.52
ADAMTS5 Q9UNA0 1/20 0.52
LMNA P02545 1/20 0.50
CTSK P43235 1/20 0.50
DRD4 P21917 1/20 0.50
LDHA P00338 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773498 0.99 TSHR (0.56) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3765124 0.97 TSHR (0.59) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3774818 0.88 ALDH1A1 (0.62) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3763154 0.87 MEN1 (0.55) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3773249 0.87 KDM2B (0.51) TSHRALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL3762993 0.87 ALDH1A1 (0.60) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3773736 0.86 MEN1 (0.72) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3760871 0.86 MEN1 (0.56) TSHRKMT2AMEN1ALDH1A1MAPT
SCHEMBL3779384 0.85 CTSB (0.51) TSHRKMT2AALDH1A1MAPTGFER
SCHEMBL3777242 0.85 MEN1 (0.55) TSHRKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TSHR 436/4885KMT2A 242/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.